Role of ST2 in Acute Pancreatitis

Completed

• Conditions: Acute Pancreatitis

• Registration Number: NCT01315613
• Lead Sponsor: Erasme University Hospital

Brief Summary

Acute pancreatitis is characterized by an inflammatory storm which regulatory pathways are not well known. The IL-1 cytokine family is activated early during acute pancreatitis and secretion of alarmins is speculated during pancreatic necrosis. IL-33 is a member of the IL-1 family, it can act as an alarmin and its receptor, ST2, is known to sequester MyD88 which might regulate the acute pancreatitis inflammatory storm. The aim of this study is to investigate ST2 pathway in human acute pancreatitis and in murine experimental models of acute pancreatitis.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Status Verified: 2008-09
• Primary Completion: 2008-09
• Study Completion: 2008-09
• Study First Submitted: 2011-03-11
• Study First Submitted QC: 2011-03-14
• Last Update Submitted: 2011-03-14
• Study First Posted: 2011-03-15
• Last Update Posted: 2011-03-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

• Time to take blood sample less than 24h after the onset of symptoms of AP
• Two of the following: typical pain, amylase and lipase concentrations more than 3x the upper normal limit, compatible modifications on imaging techniques

Exclusion Criteria

• Chronic pancreatitis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Concentration of soluble ST2 in serum	Within 30 days after onset of acute pancreatitis	Concentration of soluble ST2 will be assessed in the serum of patient with an episode of acute pancreatitis, on the day of admission to the hospital as well as 24h, 48h, 7 days and 30 days later.

Trial Locations

Locations (1)

Erasme Hospital; 🇧🇪 Brussels, Belgium